PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-168.99%
Negative EBIT growth while AGEN is at 9.77%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-230.56%
Negative operating income growth while AGEN is at 6.87%. Joel Greenblatt would press for urgent turnaround measures.
-176.90%
Negative net income growth while AGEN stands at 5.04%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
89.62%
EPS growth above 1.5x AGEN's 4.35%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
89.62%
Diluted EPS growth above 1.5x AGEN's 4.35%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2567.99%
Share count expansion well above AGEN's 0.62%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2567.99%
Diluted share count expanding well above AGEN's 0.62%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-298628.16%
Negative OCF growth while AGEN is at 9.85%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-217028.56%
Negative FCF growth while AGEN is at 10.67%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-67594.88%
Negative 10Y OCF/share CAGR while AGEN stands at 92.63%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-60146.79%
Negative 5Y OCF/share CAGR while AGEN is at 80.08%. Joel Greenblatt would question the firm’s operational model or cost structure.
-86002.39%
Negative 3Y OCF/share CAGR while AGEN stands at 45.13%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-51844.29%
Negative 10Y net income/share CAGR while AGEN is at 91.55%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-93706.66%
Negative 5Y net income/share CAGR while AGEN is 72.55%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-45701.99%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
3346.07%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
1899.20%
5Y equity/share CAGR above 1.5x AGEN's 85.92%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
720.41%
3Y equity/share CAGR above 1.5x AGEN's 36.94%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.51%
Asset growth above 1.5x AGEN's 7.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-98.43%
We have a declining book value while AGEN shows 9.21%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
92.16%
Debt growth far above AGEN's 1.16%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-30.73%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
522.30%
SG&A growth well above AGEN's 2.24%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.